Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Mouse CXCR7/RDC-1 Antibody, R&D Systems™

Sheep Polyclonal Antibody has been used in 2 publications
Supplier: R&D Systems AF4227SP
This item is not returnable.
View return policy
Description
CXCR7/RDC-1 Polyclonal specifically detects CXCR7/RDC-1 in Mouse samples. It is validated for Western Blot, Flow Cytometry, CyTOF-ready.Specifications
CXCR7/RDC-1 | |
Polyclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
ACKR3, chemokine (C-X-C motif) receptor 7, Chemokine orphan receptor 1CMKOR1C-X-C chemokine receptor type 7, CMKOR1, CXCR7, CXC-R7, CXCR-7, G protein-coupled receptor, GPR159, GPR159G-protein coupled receptor 159, RDC-1, RDC1G-protein coupled receptor RDC1 homolog | |
Sheep | |
Affinity Purified | |
RUO | |
57007 | |
Reconstitute at 0.2 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Western Blot, Flow Cytometry, CyTOF | |
LYOPH | |
Western Blot 1 ug/mL, Flow Cytometry 2.5 ug/10^6 cells, CyTOF-ready | |
P56485 | |
CXCR7 | |
Mouse myeloma cell line NS0-derived recombinant mouse CXCR7 extracellular N-terminus and loops Met1-Leu47, Ser103-Lys118, Lys184-Glu213, and Leu274-Ala296 Accession # P56485 | |
25 μg | |
Primary | |
Detects CXCR7/RDC-1 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant mouse CXCR5 is observed. | |
Mouse | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction